


GENETIC METABOLIC DISEASES

Early diagnosis and prenatal analysis

Hans Galjaard, M.D., Ph D.

*Professor of Cell Biology, Erasmus University, and
Head of the Department of Clinical Genetics,
University Hospital, Rotterdam, The Netherlands*



1980

ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS
AMSTERDAM · NEW YORK · OXFORD

© 1980 Elsevier/North-Holland Biomedical Press

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner.

ISBN 0-444-80143-X

Published by:

Elsevier/North-Holland Biomedical Press
335 Jan van Galenstraat, P.O. box 211
Amsterdam, The Netherlands

Sole distributors for the U.S.A. and Canada:

Elsevier North-Holland, Inc.
52 Vanderbilt Avenue
New York, N.Y. 10017, U.S.A.

Library of Congress Cataloging in Publication Data

Galjaard, H

Genetic metabolic diseases.

Includes bibliographies and index.

1. Metabolism, Inborn errors of--Diagnosis.
2. Prenatal diagnosis. 3. Metabolic disorders in
children--Diagnosis. I. Title.
RC627.8.G34 1980 616.3'9042 80-10216
ISBN 0-444-80143-X

The illustration on the cover is a photograph made during fetoscopy in the second trimester of gestation, and is kindly provided by Dr. R. Rauskolb, Universitätsfrauenklinik, Giessen, West-Germany.

The illustrations on p. 777 (fig. 55) is reproduced under copyright:
Al Johns 1979 c/o BIEI DRECHT Amsterdam.

PRINTED IN THE NETHERLANDS

Preface

Each time I look around in a scientific bookshop I think "why do people still write more books?"

The reason why I have nevertheless written the present book are, apart from vanity, the following.

- During the last decade there have been impressive advances in the area of early diagnosis and prenatal analysis and I thought it might be useful to put together the available data for all genetic metabolic diseases that can now be detected in early pregnancy.
- For several years our department has had the pleasure of receiving a large number of visiting scientists from many different countries who wanted to become acquainted with the techniques of (micro)biochemical analysis of cultured (hybrid) cells; I thought it might be useful for many others if details of these procedures were written down.
- In the practice of clinical genetics and as secretary of an advisory committee to the government on the organisation of early diagnosis, genetic counseling and prenatal diagnosis, I learned that most clinicians knew too little about biochemistry, that most biochemists had little idea about clinical heterogeneity and that both categories could know more about cell genetics.

I have therefore tried to write a book on the clinical features, pathological manifestations, biochemistry and (cell) genetic background of those metabolic diseases that can be diagnosed by analysis of cultured (amniotic fluid) cells. In the Appendices detailed information is given on methods allowing biochemical assays to be performed on small numbers of or single cultured cells.

This book is not meant to be read as a whole. Instead, each chapter and often each section is written in such a way that information can be derived more or less independently from the rest. Those few heroes who will read the whole book might therefore be annoyed by some duplication. I apologize to them, to my family and to my colleagues in the lab, and I promise to go to bookshops again.

Hans Galjaard

Acknowledgements

It will be no surprise to anybody when I say that a book like this could only be written with the help of many others. First of all I wish to thank the colleagues in our own department of Cell Biology and Genetics for their support, either directly by providing data or illustrations of their work, or indirectly by making me believe that writing this book was useful and even important.

In addition I have had great help from colleagues who are experts in various subjects which are dealt with in this book; their criticism and suggestions have significantly improved the quality of the particular chapters or sections. During the writing of the sections on carbohydrate metabolism I have had the support of Prof. J. Fernandes (Dept. of Pediatrics, Univ. of Groningen) and Dr. J.F. Koster (Dept. of Biochemistry, Erasmus Univ. Rotterdam); Prof. H. Kresse (Dept. of Physiological Chemistry, Univ. of Münster) helped with the section on mucopolysaccharidoses and Drs. F. van Sprang and S. Wadman (Dept. of Pediatrics, Univ. of Utrecht) and Dr. M. Mahoney (Dept. of Human Genetics, Yale University, New Haven) gave advice on the section on amino-acidopathies. Prof. D. Bootsma not only criticized the section on DNA repair but also gave me support at the moments I needed it most. I am grateful to Dr. J. Veltkamp (Dept. of Hematology, Univ. of Leiden) and to Dr. H. Busch (Dept. of Neurology, Univ. Hospital Rotterdam) for their contributions to the section on X-linked disease.

Dr. N. Horn (J.F. Kennedy Inst., Glostrup) and Dr. D.J.H. Brock (Dept. of Human Genetics, Univ. of Edinburgh) kindly provided unpublished data and I also thank all other colleagues, mentioned in the text of the book, who allowed me to use their data and illustrations. The collection of data on the practical experience with prenatal diagnosis of metabolic diseases has only been possible thanks to the cooperation of all colleagues mentioned in the list below.

My most direct collaborators, A. Hoogeveen, H.A. de Wit-Verbeek and Dr. W.J. Kleijer, have not only contributed very much to the development of many of the (micro)biochemical techniques mentioned in this book, but they have also helped me with the collection of many procedures described in the Appendices; Prof. J.F. Jongkind, Ing. J.E. de Josselin de Jong and Mr. P. Hartwijk have made important contributions to the development and testing of the instrumentation.

I wish to express my gratitude to my friends and colleagues, Dr. M.F. Niermeijer, Dr. E. Sachs, Dr. M. Jahoda and Prof. H.K.A. Visser, all of the Erasmus University and University Hospital Rotterdam, for their continuous support and always pleasant collaboration in the field of clinical genetics.

Although an author might not say so, I am proud of the high quality of the illustrations (made by Mr. W.J. Visser) and the photographs (made by Mr. J. Fengler and Mr. T.M. van Os). In the initial stage of this book Dr. G. Galavazi kindly helped me with the translation and in the final stage Ms. T.L. Bak edited the manuscript; I thank both for their patient and competent help.

Colleagues who have kindly provided their data on prenatal diagnoses

- D. Aitken and M. Ferguson-Smith, Dept. of Medical Genetics, Royal Hosp. Sick Children, Glasgow, Scotland
 P. Aula, Dept. of Pediatrics, Helsinki, Finland
 A.D. Bain and G. Besley, Royal Hospital for Sick Children, Edinburgh, Scotland
 P.F. Benson, and A. Fensom, Pediatric Research Unit, Guy's Hosp. Med. School, London, U.K.
 A. Boué and J. Boué, Groupe de Recherches de Biologie Prénatal, Paris, France
 N.J. Brandt, Klinisk Genetik Metabolisk Lab. Rigshospitalet, Copenhagen, Denmark
 D.J.H. Brock, Dept. of Human Genetics, University of Edinburgh, Scotland
 E. Buhler, Universitätskinderklinik Genet. Institut. Basel, Switzerland
 M. Cantz, Dept. of Physiological Chemistry, University of Münster, West Germany
 N. Carson, Institute of Clinical Science, Queen's University of Belfast, Ireland
 C.O. Carter, Institute of Child Health, London, U.K.
 J.C. Dreyfus and L. Poenaru, Institut Pathologie Moleculaire, Paris, France
 P. Durand, Div. Pediatrica, Istituto G. Gaslini, Genova, Italy
 K. Dörner, Universitäts-Kinderklinik, Kiel, West-Germany
 J. Farriaux, Laboratoire de Recherche de la Clinique Pédiatrique, Lille, France
 M. Fraccaro, Euratom Unit for Human Rad. and Cytogenetics, University of Pavia, Italy
 W. Fuhrmann, Institut für Human Genetik, Giessen, West Germany
 S. Girard, Laboratoire Cytogénétique, Hôpital St. Vincent-de Paul, Paris, France
 B. Goldman, Institute of Human Genetics, Chaim Sheba Medical Center, Tel Aviv, Israel
 R.A. Harkness and D. Gibbs, Clin. Res. Centre, Northwick Park Hospital, Harrow, U.K.
 K. Harzer, Institut für Hirnforschung, Universität Tübingen, West Germany

- N. Horn and M. Mikkelsen, Dept. of Human Genetics, J.F. Kennedy Institute, Glostrup, Denmark
- W.J. Kleijer, M.F. Niermeijer and E.S. Sachs, Dept. of Cell Biology and Genetics, Rotterdam, The Netherlands
- J. Leroy, Dept. of Human Genetics, University of Antwerpen, Belgium
- M. Mathieu, Service de Biochimie, Hôpital Debrousse, Lyon, France
- A. McDermott and J. Holton, S.W. Regional Cytogenetics Centre, Southmead Hosp. Bristol, U.K.
- A. Milunsky, Genetics Lab., Eunice Kennedy Shriver Center, Boston, U.S.A.
- J.D. Murken and S. Stengel-Rutkowski, Kinderpoliklinik, Universität München, West Germany
- A.D. Patrick, Institute of Child Health, University of London, U.K.
- W. Schmid, Kinderspital, Zürich, Switzerland
- M. Stockenius, Zytogenet. Unters., St. Hamburg, West Germany
- L. Svennerholm, Dept. of Neurochemistry, St. Jörgen Hospital, Göteborg, Sweden
- E. Vamos, Groupe de Diagnostic Prénatal, Hôpital St. Pierre, Bruxelles, Belgium
- M.T. Vanier, Hôpital Sainte-Eugenie, Lyon, France
- U. Wiesmann, Dept. of Pediatrics, University of Bern, Switzerland

Contents

<i>Preface</i>	<i>ix</i>
<i>Acknowledgements</i>	<i>xi</i>
<i>Chapter I – Congenital Disease and (Infant) Mortality and Morbidity</i>	<i>1</i>
1. General introduction	3
2. Incidences and recurrence risks for various categories of congenital disorders	5
2.1. Introduction	5
2.2. Diseases due to single gene mutations	6
2.3. Chromosomal aberrations	9
2.4. Congenital malformations due to abnormal embryological development	12
3. Early diagnosis and prevention	15
3.1. Introduction	15
3.2. Analysis of metabolites	16
3.3. Demonstration of the responsible protein defect	18
3.4. Investigation of the gene mutation	21
3.5. Prenatal diagnosis and prevention	23
References	30
 <i>Chapter II – Diagnosis of Genetic Metabolic Diseases</i>	 <i>39</i>
1. General introduction to early diagnosis of genetic metabolic diseases	41
References	55
2. Inborn errors of carbohydrate metabolism	58
2.1. Introduction to differential diagnosis	58
2.2. Glycogenosis type II (Pompe's disease)	64
2.3. Glycogenosis type III (Cori's disease)	68
2.4. Glycogenosis type IV (amylopectinosis; Andersen's disease)	70

2.5. Transferase deficiency galactosemia	72
References	75
3. Mucopolysaccharidoses	82
3.1. Introduction to differential diagnosis	82
3.2. Mucopolysaccharidosis IH (Hurler's disease)	93
3.3. Mucopolysaccharidosis II (Hunter's disease)	101
3.4. Mucopolysaccharidosis III (Sanfilippo's syndrome)	105
3.5. Mucopolysaccharidosis IV (Morquio's syndrome)	109
3.6. Mucopolysaccharidosis IS (former type V of Scheie's syndrome)	112
3.7. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)	115
3.8. Mucopolysaccharidosis VII	118
References	121
4. Diagnosis of mucolipidoses	132
4.1. Introduction to differential diagnosis	132
4.2. Mucolipidosis I (Sialidosis I)	135
4.3. Mucolipidosis II (I-cell disease)	137
4.4. Mucolipidosis III (pseudo-Hurler polydystrophy)	144
4.5. Mucolipidosis IV	146
4.6. α -Mannosidosis	147
4.7. Fucosidosis	151
References	158
5. Inborn errors in lipid metabolism	166
5.1. Introduction to differential diagnosis	166
References	174
5.2. Farber's lipogranulomatosis	178
References	181
5.3. Sphingomyelin lipidosis (Niemann-Pick disease)	183
References	191
5.4. Glucosylceramide lipidosis (Gaucher's disease)	195
References	202
5.5. Galactosylceramide lipidosis (globoid cell leukodystrophy or Krabbe's disease)	206
References	211
5.6. Sulfatide lipidosis or metachromatic leukodystrophy	215
5.7. Multiple sulfatase deficiency (mucosulfatidosis)	226
References	229
5.8. Ceramide trihexoside lipidosis (Anderson-Fabry disease)	237
References	246
5.9. G_{M1} -gangliosidosis	252
References	261
5.10. G_{M2} -gangliosidosis (Tay-Sachs disease and Sandhoff's disease)	266
References	281
5.11. Wolman's disease	290
References	294
5.12. Refsum's disease	297
References	300

6. Inborn errors of amino acid metabolism	303
6.1. Introduction to differential diagnosis	303
References	311
6.2. Inherited disorders in the metabolism of the urea cycle	315
6.3. Citrullinemia (argininosuccinate synthetase deficiency)	317
6.4. Argininosuccinic aciduria (argininosuccinate lyase deficiency)	320
6.5. Hyperargininemia (arginase deficiency)	323
References	325
6.6. Inherited disorders in the metabolism of branched-chain amino acids	330
6.7. Hypervalinemia and hyperleucine-isoleucinemia	333
6.8. Maple syrup urine disease	334
6.9. Isovaleric acidemia ("sweaty foot" syndrome)	340
6.10. β -Methylcrotonylglycinuria	343
6.11. α -Methylacetoacetyl-CoA β -ketothiolase (β -ketothiolase) deficiency	345
6.12. Propionic acidemia	347
6.13. Methylmalonic acidemia	351
References	355
6.14. Inherited disorders of sulfur amino acid metabolism	363
6.15. Homocystinuria	366
6.16. Cystathioninuria	379
6.17. Cystinosis	382
References	389
6.18. Defects in (hydroxy)lysine metabolism	401
6.19. Other inherited disorders of amino acid metabolism	407
References	411
7. Inborn errors in nucleic acid metabolism	415
7.1. Introduction to differential diagnosis	415
7.2. Lesch-Nyhan syndrome	422
7.3. Adenosine deaminase deficient combined immunodeficiency	436
7.4. Defective T-cell immunity (nucleoside phosphorylase deficiency)	444
7.5. Hereditary orotic aciduria	446
7.6. Xeroderma pigmentosum	448
7.7. Ataxia telangiectasia	457
References	459
8. Other genetic metabolic diseases	476
8.1. Introduction	476
8.2. Menkes' disease	477
8.3. Aspartylglucosaminuria	486
8.4. Familial hypercholesterolemia	491
References	497

Chapter III – Methodology of Prenatal Analysis in Early Pregnancy **505**

1. General introduction	507
2. Amniocentesis in early pregnancy	512

3. Induction of second-trimester abortion	526
4. Composition and analysis of amniotic fluid supernatant	531
5. Alphafetoprotein assays and prenatal detection of open neural tube defects	535
6. Cultivation of amniotic fluid cells and fetal chromosome analysis	541
6.1. Introduction	541
6.2. Amniotic fluid cell cultivation	542
6.3. Different amniotic fluid cell types	546
6.4. Fetal chromosome preparation	548
6.5. Fetal sex determination	552
7. (Micro)biochemical analysis of cultured cells	554
7.1. General aspects	554
7.2. Preparation of the cell sample and incubation procedure	556
7.3. Microspectrophotometry and microfluorometry	568
7.4. Radiometric (micro)analysis	579
7.5. Electrophoresis, chromatography and other methods of prenatal analysis	586
7.6. Relation between cell cultivation conditions and biochemical properties	590
References	597
 <i>Chapter IV – Practical Experience with Prenatal Diagnosis of Genetic Metabolic Diseases</i>	 621
1. General introduction	623
2. Prenatal diagnosis of inborn errors in carbohydrate metabolism	630
3. Prenatal diagnosis of mucopolysaccharidoses and mucopolipidoses	634
4. Prenatal diagnosis of lipidoses	641
4.1. Farber's disease	641
4.2. Niemann–Pick disease	642
4.3. Gaucher's disease	644
4.4. Krabbe's disease	645
4.5. Metachromatic leukodystrophy	646
4.6. Fabry's disease	649
4.7. GM1-gangliosidosis	650
4.8. GM2-gangliosidosis type I (Tay–Sachs disease)	652
4.9. Sandhoff's disease	655
4.10. Wolman's disease	655
5. Prenatal diagnosis of inherited aminoacidopathies	657
5.1. Citrullinemia	658
5.2. Argininosuccinic aciduria	658
5.3. Maple syrup urine disease	660
5.4. Propionic acidemia	661

5.5. Methylmalonic acidemia	662
5.6. Cystathioninuria	664
5.7. Homocystinuria	664
5.8. Cystinosis	665
6. Prenatal diagnosis of inherited disorders in nucleic acid metabolism and some other genetic defects	669
6.1. Introduction	669
6.2. Lesch-Nyhan syndrome	670
6.3. Xeroderma pigmentosum	673
6.4. Combined immune deficiency due to adenosine deaminase deficiency	676
6.5. Menkes' disease	678
6.6. Hypercholesterolemia	680
6.7. Lysosomal acid phosphatase deficiency	682
6.8. Hypophosphatasia	682
References	684
<i>Chapter V – Prevention of Sex-Linked Disease</i>	701
1. General aspects	703
2. X-linked metabolic disorders detectable by amniotic fluid cell analysis	710
2.1. Mucopolysaccharidosis II (Hunter's disease)	710
2.2. Ceramide trihexosidosis (Fabry's disease)	712
2.3. Lesch-Nyhan syndrome	713
2.4. Menkes' disease	715
3. Prevention by early diagnosis, genetic counseling and prenatal sex determination	717
3.1. Duchenne's progressive muscular dystrophy	719
3.2. Hemophilia	726
References	733
<i>Chapter VI – Some Aspects of Future Development</i>	743
1. Diagnosis and pathogenesis	745
2. Clinical treatment and basic research	751
3. Prevention and prenatal monitoring	759
References	778
<i>Appendices</i>	791
App. 1-10 – General methodology	791

App. 11–14 – Carbohydrate metabolism	809
App. 15–23 – Mucopolysaccharidoses	812
App. 24–40 – Mucolipidoses/lipidoses	817
App. 41–63 – Aminoacidopathies	830
App. 64–70 – Nucleic acid metabolism	847
App. 71–75 – Other genetic defects	853
<i>Subject index</i>	861

Chapter I

Congenital Disease and (Infant) Mortality and Morbidity

1. General introduction

Less than a hundred years ago infant mortality was in the order of 120–150⁰/∞ in most Western countries and as high as 200–300⁰/∞ in some poor rural areas and overpopulated cities. During the last century, however, there has been some general improvement but in developing countries in Africa, Latin-America and Asia with crude birth rates of 40–45/1,000, infant mortality is still 120–140⁰/∞ (McNamara's address to MIT, 1977). It is clear that in these countries improvement of economic, social, hygienic and nutritional conditions together with treatment and prevention of infectious diseases, has the highest priority.

In most industrialized countries, improvement of the living conditions has already led to a decrease of infant mortality to 15–20⁰/∞ and differences between various socio-economic groups have diminished. Health statistics in several of the wealthier countries show that congenital disease has now become the major cause of infant mortality, accounting for 25–35% of all infant deaths.

During the last decade, in the Western countries there has been increasing interest for congenital disease and human genetics. This is not only true for experts in different disciplines of medicine and psychosocial care but also for ethicists, lawyers, certain managers of industry, administrators, politicians and the general public. This broad interest seems to be due to a combination of factors:

- Congenital disorders have not only become the major cause of infant mortality, but are also responsible for a considerable proportion of infant morbidity.
- More and more couples want to limit their family size and no longer consider the birth of a handicapped child as "something one has to accept". Instead, people want extensive information about the risks of pregnancy and confinement and about the various possibilities of preventing congenital handicaps.
- During the last decade there have been major developments in the methodology of early diagnosis of patients and of carriers of genetic disease. In combination with early treatment or with proper genetic counseling and prenatal monitoring followed by selective abortion this has given new perspectives to people at risk.
- The increasing costs of health care have directed the attention of many governments towards programs that aim at the prevention of disorders which are associated with long-term physical and/or mental handicaps.
- Advances in basic research in molecular genetics, biochemistry and cell biology have been quite impressive during the last decades. The result of this research has given a better insight into the molecular basis of heredity and has led to new ways of experimental manipulation of genetic material derived from different individuals and organisms.

Not all developments in molecular research and clinical genetics have met with general enthusiasm and during the last few years there has been much debate about the ethical aspects and the possible dangers of some new methods and approaches. Although early judgement of the (possible) practical and moral merits of important scientific and clinical developments is valuable and necessary, some public discussions on human genetics have also shown shortcomings. It often seemed that emotional debate arose as a result of publicity on different issues which are not related but which have been mixed up because they were not sufficiently understood. Within a relatively short period of time people could read in nearly every newspaper or magazine: "that fetal sex and genetic disease can be detected in utero"... "gene has been synthesized in the test-tube"... "mouse \times human cell hybrids used for gene localization"... "human genes manipulated into bacteria"... and "first test-tube baby born". Who blames the layman if (s)he becomes concerned about the future when such different developments are brought into the same context? Another source of confusion is that some experts emphasize too much the potentialities of their new method without mentioning sufficiently its limitations.

In addition to new developments in basic research and clinical genetics we should also pay attention to the question whether the already existing methods of diagnosis and prevention of genetic disease are optimally used. There are still many children with a congenital disease due to a well-defined chromosomal aberration or single gene mutation, who die without proper diagnostic tests having been made. In institutes for the mentally retarded 35–65% of the patients are still undiagnosed (Moser and Wolf, 1971; Crome and Stern, 1972; Costeff et al., 1972; McDonald, 1973; Crocker, cited by Milunsky, 1975). Many patients with an adult variant of a genetic metabolic disease are not identified as such when clinicians do not think of "the unusual" or when they are not familiar with the modern methods of molecular diagnosis. In many instances lack of expertise or facilities and insufficient collaboration between people from various disciplines result in unnecessary delay in the diagnosis; this in turn has the danger that parents at risk will give birth to several affected children. Various studies indicate that even among parents of a child with a disease of recessive Mendelian inheritance 60–75% were not aware of their 1:4 recurrence risk (Taylor and Merrill, 1970; Sibinga and Friedman, 1971; McCrae et al., 1973; Hall et al., 1978). In most areas only 5–25% of the couples at risk for a genetic disease which is detectable in utero, are referred to a center for prenatal monitoring (see also Milunsky, 1976). Altogether, there are enough reasons to pay more attention to the application of available methods of early diagnosis and prevention of genetic disease. In the following section some information will be given on incidences and recurrence risks of the various categories of congenital disorders and the chapter will be completed with an introduction to early diagnosis and prevention.